anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The informal heuristic practices of the fine arts have much to offer to our understanding of the appearance of phenomenological reality. One interesting example is the use of exaggeration to enhance the illusion of liveliness in both living and nonliving subjects. This further eases the uncomfortable sense that the motion is somehow uncanny - especially with inanimate objects. We performed a series of experiments to test the effects of exaggeration on the phenomenological perception of simple animated objects - bouncing balls. A physically plausible model of a bouncing ball was augmented with a frequently used form of exaggeration known as squash and stretch. Observers were shown a series of animated balls, depicted using systematic parameterizations of the exaggeration model, and asked to rate their plausibility. A range of rendering styles provided varying levels of information as to the type of ball. In all cases, balls with small amounts of exaggeration were seen as plausible as those without any exaggeration (e.g., with veridical motion). Furthermore, when the type of ball was not specified, observers tolerated a large amount of exaggeration before judging them as implausible. When the type of ball was indicated, observers narrowed the range of acceptable exaggeration somewhat but still tolerated exaggeration well beyond that which would be physically possible. We contend that, in this case, exaggeration acts to bridge the so-called uncanny valley for artificial depictions of physical reality.
The overall objective of the High Risk Population of Cardiovascular Disease in Hubei Province (Coronary Heart Disease With Diabetes) Screening and Intervention Program（CCDInT） will be carried out in medical institutions in 14 prefecture level cities (prefectures) in Hubei province that could meet the test requirements. A total of 16,000 individuals aged ≥40 years with coronary heart disease with diabetes will be recruited into the study. Study participants will be followed in 1 year for some study outcomes. The main purpose of this study is to verify that the protocol treatment group is more effective than the conventional treatment group in reducing the incidence of composite cardiovascular disease (cardiovascular death, non fatal myocardial infarction, non fatal stroke, hospitalization for heart failure, and readmission for acute coronary syndrome) in patients with coronary heart disease and type 2 diabetes. In addition, the investigators will further study the genetic mechanism of compound cardiovascular events from the molecular genetic level, and explore the contribution and impact of genetic diversity on the treatment effect. At the same time, explore and establish a cardiovascular disease prevention and control system and effective mechanism under the leadership of provincial and municipal health administrative departments, organized by provincial prevention and control centers, and guided by municipal and state prevention and control centers, which provide theoretical and experimental basis for formulating strategies for large-scale intervention of related diseases, so as to improve the prevention and control status and effect, and strive to reduce the disease and social burden.
The present invention discloses a traditional Chinese medicine capsule and an external-pasted medicine for treating breast cancers, and preparation methods thereof. The present invention is characterized by raw materials and the preparation methods. The traditional Chinese medicine capsule for treating breast cancers comprises raw materials of scubellaria, spreading hedyotis herb, common selfheal fruit-spike, baical skullcap root, largehead atractylodesrhizome, tangerine peel, double blossom, safflower, costustoot, rhizoma corydalis, sanchi and snake skin. The external-pasted medicine comprises raw materials of arisaema, curare, olibanum, myrrh, dry toad skin, gecko, reed rhizome, realgar, Chinese honeylocust spine, musk, borneol, snail, Mongolian dandelion herb, black dog gall and honey. The traditional Chinese medicine capsule and the external-pasted medicine for treating breast cancers have the functions of integrally opsonizing, correcting excess and deficiency of either yin or yang, coordinating transportation and transformation of five-elements, adjusting incretion, and reversing cancerous cells into normal cells. The present invention adopts the methods of expelling toxins both from internals and externals, and has obvious effect, no toxic side effect, and is good medicines for treating breast cancers.
BACKGROUND: Preeclampsia is a significant pregnancy disorder with an unknown cause, mainly attributed to impaired spiral arterial remodeling.
METHODS: Using RNA sequencing, we identified key genes in placental tissues from healthy individuals and preeclampsia patients. Placenta and plasma samples from pregnant women were collected to detect the expression of TPBG (trophoblast glycoprotein). Pregnant rats were injected with TPBG-carrying adenovirus to detect preeclamptic features. HTR-8/SVneo cells transfected with a TPBG overexpression lentiviral vector were used in cell function experiments. The downstream molecular mechanisms of TPBG were explored using RNA sequencing and single-cell RNA sequencing data. TPBG expression was knocked down in the lipopolysaccharide-induced preeclampsia-like rat model to rescue the preeclampsia features. We also assessed TPBG's potential as an early preeclampsia predictor using clinical plasma samples.
RESULTS: TPBG emerged as a crucial differentially expressed gene, expressed specifically in syncytiotrophoblasts and extravillous trophoblasts. Subsequently, we established a rat model with preeclampsia-like phenotypes by intravenously injecting TPBG-expressing adenoviruses, observing impaired spiral arterial remodeling, thus indicating a causal correlation between TPBG overexpression and preeclampsia. Studies with HTR-8/SVneo cells, chorionic villous explants, and transwell assays showed TPBG overexpression disrupts trophoblast/extravillous trophoblast migration/invasion and chemotaxis. Notably, TPBG knockdown alleviated the lipopolysaccharide-induced preeclampsia-like rat model. We enhanced preeclampsia risk prediction in early gestation by combining TPBG expression with established clinical predictors.
CONCLUSIONS: These findings are the first to show that TPBG overexpression contributes to preeclampsia development by affecting uterine spiral artery remodeling. We propose TPBG levels in maternal blood as a predictor of preeclampsia risk. The proposed mechanism by which TPBG overexpression contributes to the occurrence of preeclampsia via its disruptive effect on trophoblast and extravillous trophoblast migration/invasion on uterine spiral artery remodeling, thereby increasing the risk of preeclampsia.
BACKGROUND/OBJECTIVES: Ambulatory thromboprophylaxis (AT) in patients with pancreatic adenocarcinoma (PAC) reduces venous thromboembolism (VTE) risk and is recommended for patients receiving systemic chemotherapy. We evaluated VTE rates, severity, timing, and risk factors in PAC patients as well as AT rates and initiation times.
METHODS: Patients diagnosed with PAC were included. Data collected included patient demographics, medical history, PAC diagnosis, development of VTE, AT, and bleeding episodes. VTE was defined as a DVT or a PE. Patients were classified as receiving AT for VTE prevention if they received a prescription for outpatient anticoagulation.
RESULTS: The cohort included 243 PAC patients. VTE occurred in 24 %. Overall, 52 % developing VTE were hospitalized and 5 % died as a result of the VTE. Of those who developed VTE 50 % were diagnosed within the first 2 months of PAC diagnosis. Univariate predictors of elevated VTE risk included an elevated Onkotev score, metastasis at diagnosis, male gender and not receiving AT. Multivariate predictors of elevated VTE risk included male gender (P = 0.014) and not receiving AT (P = 0.001). Overall, 30 % of patients received AT. The median time from diagnosis to initiation of AT was 43 days. Major bleeding occurred in 5.8 %. Patients receiving AT were not at a significantly increased risk of major bleeding (p = 0.5). Patients with intestinal tumor invasion were at significantly increased risk of major bleeding (P = 0.021).
CONCLUSION: VTE risk is significant and morbid in PAC patients. AT rates are low, and initiation is often delayed. Therapeutic endoscopists diagnosing PAC may be helpful in AT initiation.
Maternal separation (MS), a form of early life adversity, increases the risk of psychiatric disorders in adulthood by intricately linking cytokines and mood-regulating brain circuits. The Lateral Habenula (LHb) encodes aversive experiences, contributes to negative moods, and is pivotal in depression development. However, the precise impact of MS on LHb cytokine signaling and synaptic plasticity remains unclear. We reported that adolescent MS offspring mice displayed susceptibility to depression behavioral phylotypes, with neuronal hyperactivity and an imbalance in pro-inflammatory and anti-inflammatory cytokines in the LHb. Moreover, the decreased IL-10 level negatively correlated with depressive-like behaviors in susceptible mice. Functionally, LHb IL-10 overexpression restored decreased levels of PI3K, phosphorylated AKT (pAKT), gephyrin, and membrane GABAA receptor proteins while reducing abnormally elevated GSK3β and Fos expression, rescuing the MS-induced depression. Conversely, LHb neuronal IL-10 receptor knockdown in naive mice increased Fos expression and elicited depression-like symptoms, potentially through impaired membrane GABAA receptor trafficking by suppressing the PI3K/pAKT/gephyrin cascades. Hence, this work establishes a mechanism by which MS promotes susceptibility to adolescent depression by impeding the critical role of IL-10 signaling on neuronal GABAA receptor function.
The invention provides a denture liner composition for a composite denture based on a phosphonitrilic fluoroelastomer [poly(fluoroalkoxy)phosphazene] curable at atmospheric pressure at temperatures of about 100° C. or less, conveniently by immersing the packed denture flask in a water bath at the appropriate temperature. The composition includes trimethacrylate and dimethacrylate cross-linking agents for increasing liner hardness and decreasing water sorption characteristics of the cured liner. The composition preferably further includes filler materials for increasing the hardness of the liner product. The composite denture is preferably prepared in a one-step process wherein the liner composition material of a single firmness is cured in situ with the denture base material. Alternatively, a firm liner material is cured at the periphery of the denture, and a softer liner material cured at the center; this provides a firm elastic liner adjustable by grinding where soft tissues must be displaced, and a soft elastic liner over bony anatomy, where stresses from chewing are most concentrated and soft tissues are thin. Another possibility lies in curing the soft liner directly to a precured denture as a reline procedure in an pre-existing denture.
Pediatric participants with severe VWD (self-pediatric bleeding questionnaire \[PBQ\] score of ≥3 for at least one symptom and caregivers will be enrolled as per protocol specifications. Data will be collected from participants via questionnaire, semi-structured interviews, and focus groups using a virtual platform. The decision to proceed with Phase 2 will be determined following completion of Phase 1.
<P>PROBLEM TO BE SOLVED: To provide a composition for applying to mucous membranes, which improves the wettability of corneal surfaces and contact lens surfaces.  <P>SOLUTION: This composition for applying to the mucous membranes is characterized by containing sodium carboxymethylcellulose and a terpenoid. The composition improves the wettability of corneal surfaces and contact lens surfaces. Thereby, the wettability is maintained, and the touch feeling of the contact lenses are improved. The composition further has an excellent effect for preventing mucosal dryness symptoms such as dry eyes and excellent effects for preventing or improving various diseases caused by dryness.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Pregnancy and breast feeding are protective when they occur at an early age, typically at an age less than 30. The influence of pregnancy on breast cancer risk is not fully understood, and little is known about modulation of the breast microenvironment during pregnancy and its influence on risk. Hormones, including rising estrogen levels, play a role in fatty acid synthesis. In pre-clinical models, a rise in omega-3:omega-6 ratio occurs naturally in the breast of pregnant mice. This may be able to be accentuated in human breast tissue with omega-3 fatty acid supplementation. Omega-3 fatty acid supplementation has been shown to favorably modulate breast cancer risk and risk biomarkers in pre-menopausal women at high risk for breast. Omega-3 fatty acid supplementation during pregnancy has also been found to have positive outcomes for the offspring, making it an ideal intervention to study in this population.

This pilot study of omega-3 supplementation in pre-menopausal women at high risk for breast cancer who are still considering pregnancy is addressing a potential prevention strategy in a population otherwise excluded from breast cancer prevention trials and not eligible for standard of care chemoprevention. With this pilot, the intent is to establish feasibility, document tolerability, determine number of women needed to enroll based on pregnancy rate and identify biomarkers for future investigation. This information will provide necessary data to apply for future extramural funding for a larger randomized trial. In a larger randomized trial with longer follow up, we will be able to assess post-pregnancy breast tissue and biomarkers to examine efficacy of omega-3 fatty acid supplementation in breast cancer risk reduction.
Participants randomly assigned to this arm will receive placebo nasal spray at laboratory visit 1 and OT nasal spray (24 IU) at visit 2. The order will be masked for participants and study staff.
The present invention relates to a cosmetic process which applies onto the skin a self-standing cosmetic sheet for the skin, comprising: . at least one biocompatible and/or biodegradable hydrophobic polymer layer . wherein . the self-standing cosmetic sheet has a thickness of from 10 to 1000 nm, preferably from 30 to 500 nm, and more preferably from 50 to 300 nm. The cosmetic sheet according to the present invention may comprise at least one cosmetic active ingredient. The cosmetic sheet used in the present invention is very thin and not easily perceived on the skin; can be prepared with a variety of materials such as a biocompatible and/or biodegradable material, preferably non-cross-linked poly(lactic acid) or a combination of chitosan and alginic acid; and can adhere well onto the skin without any adhesive layer so that it is less irritable or no irritable to the skin.
Techniques for patient data management include obtaining medical history data of patients from a database, the medical history data including a history of one or more diagnosis events, one or more treatment events, and a clinical outcome event for each patient of the patients. For each patient, based on the medical history data, a computing system generates a patient pathway that includes a graph including nodes of one or more diagnosis events, the one or more treatment events, and the clinical outcome event. The computing system receives, via an interface, one or more criteria to select a subset of the patient pathways of the patients. The computing system selects, based on the one or more criteria, graphs representing the subset of the patient pathways. The computing system aggregates the subset of the patient pathways into a merged graph. The computing system displays the merged graph in the interface.
A wearable personal activity monitor 95 has an accelerometer to sense extent of movement of a user and a wireless communication module to receive data from physiological data gathering devices (e.g. weighing scales 120, body composition analysis monitor 121, blood pressure monitor 122). Data may also be received from exercise equipment 123. The monitor 95, which may be worn on the wrist or ankle, stores movement data and physiological data over a period of time and can transmit the data over the internet 92 to a computer based coaching system 90 on a server 91. The coaching system interacts with the user, via web pages. The user can input data relating to physical or mental condition, and plan a schedule of activities and lifestyle. The system provides suggestions, hints, tips and recommendations as to forms of exercise and lifestyle. Links to other users of the system are provided. The system displays a commitment meter.
Palonosetron is eliminated from the body through both renal excretion and metabolic pathways with the latter mediated via multiple CYP enzymes. In vitro studies indicated that palonosetron is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6, or CYP3A4/5. Therefore, the potential for clinically significant drug interactions with palonosetron appears to be low.

A study in healthy volunteers involving single-dose IV palonosetron (0.75 mg) and steady state oral metoclopramide (10 mg four times daily) demonstrated no significant pharmacokinetic interaction.

In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents.

Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C) in murine tumor models.
Participants will receive mifepristone 200 mg by mouth 24 hours prior to induction of labor. Participants will have their labor induced concomitantly with misoprostol (according to the regimen described in the "Usual Care" arm) and placement of the Cook Cervical Ripening Balloon.
Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.
Prescribing dicloxacillin sodium capsules in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Dicloxacillin should generally not be administered to patients with a history of sensitivity to any penicillin.

Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma. Whenever allergic reactions occur, penicillin should be withdrawn unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to penicillin therapy.

The oral route of administration should not be relied upon in patients with severe illness, or with nausea, vomiting, gastric dilatation, cardiospasm or intestinal hypermotility. Occasionally, patients will not absorb therapeutic amounts of orally administered penicillin.

The use of antibiotics may result in overgrowth of nonsusceptible organisms. If new infections due to bacteria or fungi occur, the drug should be discontinued and appropriate measures taken.
508,715. Obtaining iodine and cellulose from seaweed. DILLON, T., FLOOD, D. T., BARRY, V. C., and O'MUINEACAIN, P. Jan. 20, 1938, No. 1892. Convention date, May 5, 1937. [Class 90] [Also in Group IV] Iodine and other substances are obtained by digesting seaweed with a weak aqueous acid solution, e.g. dilute sulphuric acid, separating the acid extract and treating it, preferably hot, with insoluble copper compounds, e.g. cuprous chloride or cuprous oxide to form copper iodide compounds which are separated by filtration or sedimentation. Iodine is then recovered by known methods. Further acid is added to the liquor remaining and is used for further extraction. When the content of potash and other salts and organic bodies such as mannitol in the liquor becomes too great for useful extraction, such salts &c. may be recovered by any suitable method or the acid content may be neutralized, e.g. with lime and the mass evaporated for use as a fertilizer. The seaweed may be digested in the natural state, or it may be fermented or wetted before it is digested. The Specification as open to inspection under Sect. 91 includes also the subject-matter of Specification 508,671, [Group IV]. This subjectmatter does not appear in the Specification as accepted.
PROBLEM TO BE SOLVED: To obtain a specific new triene-based compound derived from microorganism, having antimycotic activity with new mechanism and useful for e.g. the treatment of opportunistic internal organ mycoses of persons declined in biophylactic function due to anticancer agent administration or AIDS. SOLUTION: This new triene-based compound WSS1042 shown by the formula has antimycotic activity and useful for e.g. the treatment of opportunistic internal organ mycoses of persons declined in biophylactic function due to anticancer agent administration or AIDS. This compound of the formula is obtained by the following procedure: Streptomyces sp. TA-0323 (FERM P-16732), a strain capable of producing the active substance WSS1042, is inoculated upon a sterile culture medium followed by carrying out a rotary shaking culture at 26 deg.C and 160 rpm for 5 days to make a seed culture fluid, which, in turn, is put into a jar fermenter packed with a sterile liquid medium followed by a submerged culture at 26 deg.C for 92 h, and the resulting product is extraction-treated and then fractionated with a column to effect purification.
Limited data exist on HPV prevalence and genotyping during the COVID-19 pandemic. A total of 130,243 samples from 129, 652 women and 591 men who visited the First People's Hospital of Linping District between 2016 and 2022 were recruited. HPV genotypes were detected by polymerase chain reaction (PCR) amplification and nucleic acid molecular hybridization. Then the prevalence characteristics of HPV genotypes and trends in HPV infection rates from 2016 to 2022 were analyzed. Results showed that among the study population, the overall prevalence of HPV infection was 15.29%, with 11.25% having single HPV infections and 4.04% having multiple HPV infections, consistent with previous findings. HPV genotypes exhibited similar distribution patterns in both male and female groups, with HPV16, HPV52, HPV58, HPV18, and HPV39 being the most prevalent. Age-related analysis unveiled a bimodal pattern in HPV prevalence, with peaks in infection rates observed in individuals below 20 and those aged 61-65 years. Comparing the pre- and during COVID-19 periods revealed significant disparities in HPV infections, with variations in specific HPV genotypes, including 16, 18, 35, 45, 52, 58, 59, and 68. This study provides valuable insights into the prevalence, distribution, and epidemiological characteristics of HPV infections in a large population. It also highlights the potential impact of the COVID-19 pandemic on HPV trends.
HeezOn Ultra-1 includes ingredients like Shilajit, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.